As of May 24, 2025, Cara Therapeutics Inc (CARA) reports a ROA (Return on Assets) of -161.70%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Cara Therapeutics Inc's ROA (Return on Assets)
Over recent years, Cara Therapeutics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -161.70% |
| 2023-12-31 | -94.17% |
| 2022-12-31 | -46.93% |
| 2021-12-31 | -35.77% |
| 2020-12-31 | 3.10% |
This slight downward trend highlights how Cara Therapeutics Inc manages its efficiency in using assets to generate earnings over time.
Comparing Cara Therapeutics Inc's ROA (Return on Assets) to Peers
To better understand Cara Therapeutics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Cara Therapeutics Inc (CARA) | -161.70% |
| Redhill Biopharma Ltd (RDHL) | 103.77% |
| Zoetis Inc (ZTS) | 17.46% |
| Merck & Co Inc (MRK) | 14.62% |
| Eli Lilly and Co (LLY) | 13.45% |
| Johnson & Johnson (JNJ) | 7.81% |
Compared to its competitors, Cara Therapeutics Inc's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.